Where Does Wall Street Think FibroGen Inc (FGEN) Stock Will Go?

Wall Street is positive on FibroGen Inc (FGEN). On average, analysts give FibroGen Inc a Hold rating. The average price target is $4.375, which means analysts expect the stock to gain by 333.17% over the next twelve months. That average ranking earns FibroGen Inc an Analyst Rating of 2, which is better than 2% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating FGEN a Hold today. Find out what this means to you and get the rest of the rankings on FGEN!

See Full FGEN Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With FibroGen Inc Stock Today?

FibroGen Inc (FGEN) stock is lower by -8.56% while the S&P 500 has gained 0.39% as of 10:42 AM on Monday, Sep 11. FGEN has fallen -$0.10 from the previous closing price of $1.11 on volume of 493,129 shares. Over the past year the S&P 500 is higher by 8.87% while FGEN has fallen -92.30%. FGEN lost -$3.39 per share the over the last 12 months. Click Here to get the full Stock Report for FibroGen Inc stock.